Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash from Financing Activities: 2017-2025

Historic Cash from Financing Activities for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $3.1 million.

  • Crinetics Pharmaceuticals' Cash from Financing Activities fell 94.62% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $566.6 million, marking a year-over-year increase of 14.15%. This contributed to the annual value of $1.0 billion for FY2024, which is 159.79% up from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $3.1 million for Q3 2025, which was down 56.29% from $7.1 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Cash from Financing Activities ranged from a high of $552.0 million in Q4 2024 and a low of $57,000 during Q1 2021.
  • Moreover, its 3-year median value for Cash from Financing Activities was $12.7 million (2023), whereas its average is $128.5 million.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Cash from Financing Activities skyrocketed by 168,823.71% in 2021 and then slumped by 99.93% in 2022.
  • Over the past 5 years, Crinetics Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at $163.9 million in 2021, then tumbled by 99.93% to $115,000 in 2022, then skyrocketed by 32,878.26% to $37.9 million in 2023, then spiked by 1,355.53% to $552.0 million in 2024, then slumped by 94.62% to $3.1 million in 2025.
  • Its Cash from Financing Activities stands at $3.1 million for Q3 2025, versus $7.1 million for Q2 2025 and $4.4 million for Q1 2025.